Bitcoin long-term holders decreased their supply by 22% in the week ending October 29, dropping from 310,000 BTC to 240,000 BTC over 30 days. Their unrealized profit margin also narrowed slightly, with the MVRV ratio falling from 1.67 to 1.65, indicating the market price is 65% above their average cost basis of $48,000. This suggests easing sell pressure among long-term holders, who still hold significant unrealized profits. A rise in the MVRV ratio could signal profit margin recovery, while further price drops might threaten long-term holder supply.
Bitcoin long-term holders reduced their supply by 22% over the past month, holding 240,000 BTC as of October 29, 2026. For readers following cryptocurrency markets, here is Pluang's market snapshot as of Oct 29, 2026 14:02 WIB: out of 50 major cryptocurrencies, 7 rose and 42 fell today. Notable movers include FIL at Rp16.002 with a 4.19% decline and balanced Pluang order activity, THETA at Rp3.150 down 3.73% with 100% sell orders, and ADA at Rp3.611 down 3.68% with 72% sell orders.
TGS ASA announced that its shares will be traded ex-dividend at NOK 1.45 per share starting October 29, 2026. This means investors buying the stock from this date will not receive the upcoming dividend payment. The dividend distribution follows appro...
DNO ASA, a Norwegian oil and gas company, announced a cash dividend of NOK 0.375 per share to be paid around November 17, 2026. Shareholders registered by November 9, 2026, will receive the dividend, with shares trading ex-dividend starting November ...
Oil prices fell sharply after reports emerged that U.S. Vice President JD Vance contacted Iranian officials to restart peace negotiations, easing fears of supply disruptions from Middle East conflicts. Brent crude dropped 1.23% to $113.9 per barrel, ...
A post on X from The Bitcoin Historian account attributed to Fidelity Investments suggests investors increasingly view Bitcoin as a safe-haven asset and hints at renewed upward momentum. It also referenced a previous post predicting Bitcoin could rea...
Johnson & Johnson reported Q3 revenue of $25.4 billion, driven by a 7.9% operational growth in its Innovative Medicine segment, while its MedTech division grew only 2.5%. The company raised its 2026 revenue guidance slightly to $101.2 billion, up fro...
